AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 6 - (NewsRx.com & NewsRx.net) --
Early results from a small study of metastatic lung and colorectal cancer patients indicate that a vaccine made from genetically-altered cancer cells resulted in a dramatic regression of cancer in some patients with end-stage colorectal disease.
The vaccine was produced through a novel two-step process designed to boost the ability of a patient's immune system to attack cancer cells. Researchers first used a drug, FLT-3 ligand, to expand by 20 times the number of dendritic cells within a patient, and then extracted the cells from the patient's blood. The dendritic cells - rare, specialized cells that tell the immune system what to look for - were then altered to display a protein known as carcinoembryonic antigen (CEA) that is overexpressed by most gastrointestinal cancer cells. The genetically engineered CEA protein was also designed to be slightly different from the natural protein so that it could be more easily "seen" by the body's immune system cells.
When the altered dendritic cells were injected back into patients, they stimulated a potent immune response that targeted CEA proteins on cancer cells.
"The study demonstrates that a protein expressed in common malignancies can be vaccinated against and may ultimately be applicable to many ...
Source: HighBeam Research, Cancer Vaccine Produces Response In Patients With Late Stage...